The Board granted a 30 percent rating for pseudofolliculitis barbae, with eczematous dermatitis, tinea cruris, tinea pedis and vitiligo for the period on appeal prior to April 6, 2023, but denied a higher rating for the entire period on appeal.

The deciding factor: The record is in approximate balance as to whether the criteria for a 30 percent rating were met for the period on appeal prior to April 6, 2023, and no evidence suggests a higher level of involvement or systemic therapy over the past 12-month period.

Claimed conditions

pseudofolliculitis barbae, with eczematous dermatitis, tinea cruris, tinea pedis, vitiligo

How they argued it

Direct service connection

Exposure basis

None

Rating assigned

30%

Decision date

October 23, 2025

Citation

25013212

Want to see how appeals like this one tend to go? Appeals like mine